Marker Therapeutics Inc MRKR:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 2:58 PM EDT
0.308quote price arrow up+0.008 (+2.67%)
Volume
120,758
52 week range
0.28 - 3.65
Loading...
  • Open0.3046
  • Day High0.308
  • Day Low0.2932
  • Prev Close0.30
  • 52 Week High3.65
  • 52 Week High Date06/14/21
  • 52 Week Low0.28
  • 52 Week Low Date05/12/22

Key Stats

  • Market Cap25.75M
  • Shares Out83.60M
  • 10 Day Average Volume0.20M
  • Dividend-
  • Dividend Yield-
  • Beta1.50
  • YTD % Change-68.43

KEY STATS

  • Open0.3046
  • Day High0.308
  • Day Low0.2932
  • Prev Close0.30
  • 52 Week High3.65
  • 52 Week High Date06/14/21
  • 52 Week Low0.28
  • 52 Week Low Date05/12/22
  • Market Cap25.75M
  • Shares Out83.60M
  • 10 Day Average Volume0.20M
  • Dividend-
  • Dividend Yield-
  • Beta1.50
  • YTD % Change-68.43

RATIOS/PROFITABILITY

  • EPS (TTM)-0.52
  • P/E (TTM)-0.60
  • Fwd P/E (NTM)-0.62
  • EBITDA (TTM)-38.221M
  • ROE (TTM)-79.50%
  • Revenue (TTM)2.21M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-1,949.65%
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date08/08/2022(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Marker Therapeutics Inc

There is no recent news for this security.

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company specializes in the development and commercialization of T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The Company has developed its lead product candidates from its MultiTAA-specific T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor...
Frederick Wasserman CPA
Independent Chairman of the Board
N. David Eansor
Independent Chairman of the Board
Peter Hoang
President, Chief Executive Officer, Director
Juan Vera M.D.
Chief Operating Officer, Chief Scientific Officer, Director
Anthony Kim
Chief Financial Officer
Michael Loiacono
Chief Accounting Officer, Treasurer, Secretary
Anna Szymanska
Vice President - Quality
Address
3200 SOUTHWEST FREEWAY, SUITE 2250
Houston, TX
77027
United States

Top Peers

SYMBOLLASTCHG%CHG
BCDA
BioCardia Inc
1.67+0.07+4.37%
AYLA
Ayala Pharmaceuticals Inc
1.53-0.17-9.98%
CYTH
Cyclo Therapeutics Inc
2.18+0.08+3.81%
CANF
Can Fite Biopharma Ltd
0.90+0.045+5.26%
MNPR
Monopar Therapeutics Inc
2.25UNCHUNCH